Loading...
Loading...
BGNE| Name | Value |
|---|---|
| Revenues | 634.4M |
| Cost of Revenue | 128.5M |
| Gross Profit | 505.9M |
| Operating Expense | 889.7M |
| Operating I/L | -383.8M |
| Other Income/Expense | 33.0M |
| Interest Income | 21.0M |
| Pretax | -350.8M |
| Income Tax Expense | 16.8M |
| Net Income/Loss | -367.6M |
BeiGene, Ltd. is a global biotechnology company specializing in the discovery, development, manufacturing, and commercialization of a diverse range of medicines. The company's product portfolio includes innovative treatments for various cancers and hematological disorders, such as BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, and Pobevcy. Additionally, BeiGene's clinical stage drug candidates encompass promising therapies targeting lymphomas, solid tumors, and hematological cancers. The company generates revenue through the sale of its approved medicines and potential future commercialization of its clinical stage drug candidates.
